August 1, 2017 07:58 AM EDTUpdated 10:12 AM

After taking a PhIII thrashing, AstraZeneca comes out swinging with breakthrough titles, new cancer hires

AstraZeneca $AZN may be down, but it’s not out.

Sent reeling over the failure of its first big primary endpoint for a checkpoint combo …

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Af­ter tak­ing a PhI­II thrash­ing, As­traZeneca comes out swing­ing with break­through ti­tles, new can­cer hires